Was phenserine a failure or were investigators mislead by methods?

Current Alzheimer Research

Volumn 9, Issue 10, 2012, Pages 1174-1181

  Becker, Robert E ^a,b   Greig, Nigel H ^b  

^a Aristea Translational Medicine Corp   (United States)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Alzheimer's disease; Clinical translation; Neuropsychiatric drug development; Phenserine; Placebo group improvement; Scientific practices in drug development; Validity; Variance

Indexed keywords

PHENSERINE;

ALZHEIMER DISEASE; ARTICLE; COGNITION; DRUG EFFICACY; DRUG MONITORING; DRUG TREATMENT FAILURE; HUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MEDLINE; PHYSOSTIGMINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT FAILURE;

EID: 84874893873     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512804142912     Document Type: Article

References (39)

1. Kreeger KY. Overdue, first-time recognitions mark '95 nobel science, peace prizes. The Scientist, November 13, 1995: http://classic.the-scientist.com/?articles.view/articleNo/17647/ Viewed August 15, 2012.
2. Khachaturian ZS, Barnes D, Einstein R, Johnson S, Lee V, Roses A, et al. Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement 6: 89-97 (2010).
3. Vellas B, Aisen PS, Sampaio C, Carrillo M, Scheltens P, Scherrer B, et al. Prevention trials in Alzheimer's disease: an EU-US task force report. Prog Neurobiol 95: 594-600 (2011).
4. Vellas B, Hampel H, Rougé-Bugat ME, Grundman M, Andrieu S, Abu-Shakra S, et al. Alzheimer's Disease Therapeutic Trials: EU/US Task Force Report on Recruitment, Retention, and Methodology. J Nutr Health Aging 16: 339-45 (2012).
5. Hampel H, Wilcock G, Andrieu S, Aisen P, Blennow K, Broich K, et al. Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol 95: 579-93 (2011).
6. Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology 76: 280-6 (2011).
7. Paul SM, Mytelka DS, Dunwiddle CT, Persinger CC, Numos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Reviews: Drug Discovery 5: 203-14 (2010).
8. Lansbury PT. Back to the future: the 'old fashioned' way to new medications for neurodegenerations. Nature Rev Neurosci 5: S51-S57 (2004).
9. Klein DF. The loss of serendipity in psychopharmacology. JAMA 299:1063-5 (2008).
10. Pangalos MN, Schechter LE, Hurko O. Drug development for CNS disorders: Strategies for balancing risk and reducing attrition. Nat Rev Drug Discov 6: 521-32 (2007).
11. Markou A, Chiamulera C, Geyer MA, Tricklebank M, Steckler T. Removing obstacles in neuroscience drug discovery: The future path for animal models. Neuropsychopharmacol 34: 74-89 (2009).
12. Collins FS. Reengineering translational science: the time is right. Sci Transl Med 3:90-117 (2011).
13. Lindner MD, McArthur RA, Deadwyler SA, Hampson RE, Tariot PN. Development, optimization and use of preclinical behavioral models to maximize the productivity of drug discovery for Alzheimer's disease. In: Animal and Translational Models for CNS Drug Discovery: Neurologic Disorders. (Ed., McArthur RA, Borsini F) Academic Press; San Diego: pp. 93-157 (2008).
14. Greig NH, Ruckle J, Comer P, Brownell L, Holloway HW, Flanagan DR et al. Anticholinesterase and pharmacokinetic profile of phenserine in healthy elderly human subjects. Curr Alzheimer Res 2: 483-92 (2005).
15. Shaw KT, Utsuki T, Rogers J, Yu QS, Sambamurti K, Brossi A, et al. Phenserine regulates translation of beta-amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. PNAS 98:7605-10, (2001).
16. Lahiri DK, Chen D, Vivien D, Ge YW, Greig NH, Rogers JT. Role of cytokines in the gene expression of amyloid beta-protein precursor: identification of a 5'-UTR-binding nuclear factor and its implications in Alzheimer's disease. J Alzheimers Dis 5: 81-90 (2003).
17. Rogers JT, Leiter LM, McPhee J, Cahill CM, Zhan SS, Potter H, et al. Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5'-untranslated region sequences. J Biol Chem 274: 6421-31 (1999).
18. Mikkilineni S, Cantuti-Castelvetri I, Cahill CM, Greig NH, Rogers JT. The anti-cholinesterase phenserine and its enantiomer posiphen as 5'untranslated region directed translation blockers of the Parkinson's alpha synuclein expression. Parkinson's Disease. In press, (2012).
19. Venti A, Giordano T, Eder P, Bush AI, Lahiri DK, Greig NH, et al. The Integrated Role of Desferrioxamine and Phenserine Targeted to an Iron-Responsive Element in the APP-mRNA 5'-Untranslated Region. Ann NY Acad Sci 1035: 34-48 (2004).
20. Sambamurti K, Prakasam A, Anitha S, Venugopa C, Cullen E, Zhou Y, et al. Oral phenserine tartrate treatment is associated with reduced plasma Aβ 1-42 in a phase I clinical study. In, Alzheimer's Disease New Advances (Ed., Khalid IK, Winblad B, Avila J) Medimond, Via Maserati 5, Bologna, Italy, pp. 571-5 (2007).
21. Thatte U. Phenserine Axonyx. Current Opinion in Investigational Drugs 6: 729-39 (2005).
22. Kadir A, Andreasen N, Almkvist O, Wall A, Forsberg A, Engler H, et al. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol 63: 621-31 (2008).
23. Winblad B, Giacobini E, Frölich L, Friedhoff LT, Bruinsma G, Becker RE, et al. Phenserine efficacy in Alzheimer's disease. J Alzheimer Dis 22:1201-8 (2010).
24. Becker RE, Greig NH, Giacobini E. Why Do So Many Drugs for Alzheimer's Disease Fail in Development? Time for New Methods and New Practices? J Alzheimer Dis 15: 303-25 (2008).
25. Hoaglin DC, Mosteller F, Tukey JW. Understanding Robust and Exploratory Data Analyses. John Wiley & Sons, New York, NY (2000).
26. Siegel S: Non-Parametric Statistics. McGraw Hill, New York, NY (1956).
27. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 141:1356-64 (1984).
28. Becker RE, Markwell S. Problems arising from the generalizing of treatment efficacy from clinical trials in Alzheimer's disease. Clin Drug Invest. 19:33-41 (2000).
29. Becker RE. Lessons from Darwin: 21st Century designs for clinical trials. Curr Alzheimer Res 4: 458-67 (2007).
30. Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, Jin S, et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology 76:1389-94 (2011).
31. Aisen PS, Schneider LS, Sano M, Diaz-Arrastia R, van Dyck CH, Weiner MF, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 300:1774-83 (2008).
32. Cohen J. Things I have learned (so far). Amer Psychologist 45:1304-12 (1990).
33. Schneider LS, Sano M. Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimers Dement 5: 388-97 (2009).
34. Becker RE, Colliver JA, Markwell SJ, Moriearty PL, Unni LK, Vicari S. A double-blind, placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer's disease. Alzheimer Dis Assoc Disord 10:124-31 (1996).
35. Becker RE, Colliver JA, Markwell SJ, Moriearty P, Unni LK, Varney A, et al. A six month study of the effects of metrifonate on cognitive decline in Alzheimer's disease. Alzheimer Dis Assoc Disord 12:54-7 (1998).
36. Engelhardt N, Feiger AD, Cogger KO, Sikich D, DeBrota DJ, Lipsitz JD, et al. Rating the raters: assessing the quality of Hamilton rating scale for depression clinical interviews in two industry sponsored clinical drug trials. J Clin Psychopharmacol 26: 71-4 (2006).
37. McDermott T. Scientists can't get their minds around Alzheimer's. Los Angeles Times December 27, 2007. http://www.latimes.com/news/printedition/front/la-naalzheimers27dec27,0,1738791. story. Viewed August 15 (2012).
38. Duhem P. The Aim and Structure of Physical Science. Princeton: Princeton University Press (1991).
39. Becker RE, Greig NH. Why so few drugs for Alzheimer's disease? Are methods failing drugs? Curr Alzheimer Res 7: 642-51 (2010).